Researchers profiled the metabolic breakdown of amylin-based weight loss drugs (pramlintide, cagrilintide, KBP-042) to develop anti-doping detection methods.
WADA monitoring since 2024Semaglutide already tracked; next-gen amylin drugs may follow
What the researchers found
In vitro metabolic profiling identified breakdown products of pramlintide, cagrilintide, and KBP-042, supporting development of anti-doping detection methods for next-generation weight loss peptides.
Why it matters
As weight loss peptides become more accessible, sports organizations need validated detection methods to prevent misuse in weight-sensitive athletic disciplines.
How the study worked
In vitro metabolic profiling using laboratory-based incubation systems to identify metabolites of amylin receptor agonists.
What this study cannot tell us
In vitro metabolic profiling may not perfectly replicate in vivo metabolism; actual detection windows in athletes need validation through in vivo studies.
How to read the evidence
In vitro laboratory study — foundational for method development but requires in vivo validation for practical anti-doping application.
When this study was published
Published 2026. Addresses emerging concern as weight loss peptides gain popularity.
The bigger picture
The intersection of obesity pharmacotherapy and anti-doping enforcement is a growing concern as potent weight loss drugs become widely available and tempting for competitive athletes.
Questions still open
- How long are these metabolites detectable in urine or blood after use?
- Will WADA move amylin agonists to its prohibited list?
Common questions
Why would athletes misuse weight loss drugs?
Are these weight loss drugs currently banned in sports?
Read the original research
In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
Journal of pharmaceutical and biomedical analysis, 273, 117418
Citation
Alhalabi, Hana; Borschel, Lisa; Le Foll, Christelle; Thomas, Andreas; Bally, Lia; Thevis, Mario. (2026). In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.. Journal of pharmaceutical and biomedical analysis, 273, 117418. https://doi.org/10.1016/j.jpba.2026.117418